Open AccessMode of Action of RZL-012, a New Fat-Reducing Molecule
Author(s) -
Eran Blaugrund,
Racheli Gueta,
Anton Zernov,
Alon Bloomenfeld
Publication year - 2021
Publication title -
dermatologic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.659
H-Index - 125
eISSN - 1524-4725
pISSN - 1076-0512
DOI - 10.1097/dss.0000000000003245
Subject(s) - adipocyte , adipose tissue , in vivo , membrane permeability , calcium , chemistry , cell , fat pad , endocrinology , cytosol , pharmacology , membrane integrity , medicine , membrane , biology , biochemistry , enzyme , microbiology and biotechnology
RZL-012 (5-[3,6-dibromo-9H-carbazol-9-yl]-N,N,N-trimethylpentan-1-aminium chloride) is a novel investigational drug injected subcutaneously into fat tissues in patients with fat-related disorders (Dercum disease) or subjects seeking aesthetic changes.